Skip to main content

SGLT2 inhibitors: Cost Comparison

SGLT2 (sodium-glucose cotransporter-2) inhibitors lower blood sugar by making the kidneys remove glucose in urine, and are also used in heart failure and chronic kidney disease.

Across these 2 drugs, average Medicare Part D spending per dosage unit ranges from $18.31 (Farxiga) to $18.94 (Jardiance) for calendar year 2024. Figures are real CMS open data, in US dollars.

How much do sglt2 inhibitors cost in the US?

As of calendar year 2024, average Medicare Part D spending per dosage unit for these 2 sglt2 inhibitors ranged from $18.31 (Farxiga) to $18.94 (Jardiance), per CMS open data. These are Medicare program spending figures per billing unit — not pharmacy cash prices, and not medical advice.

Source:CMS Medicare Part D Spending by Drug·as of calendar year 2024updated yearly (last: )
Not medical advice — and not a like-for-like price. Each figure is average Medicare Part D program spending per dosage unit, taken unchanged from a public US government dataset. A “dosage unit” differs between drugs (one tablet, one mL, one pen, etc.), so a higher per-unit figure does not always mean a higher monthly cost. These are not pharmacy cash prices, not per-prescription costs, and not price quotes. Always consult a licensed pharmacist or clinician about type 2 diabetes, heart failure and chronic kidney disease.
SGLT2 inhibitors — CMS Medicare Part D average spending per dosage unit, calendar year 2024 (CMS, public domain)
DrugGeneric (active ingredient)Avg Part D spending / dosage unit2024 Part D claims
JardianceEmpagliflozin$18.9411,368,280
FarxigaDapagliflozin Propanediol$18.315,634,650

Figures are CMS’s own published Medicare Part D spending values (field Avg_Spnd_Per_Dsg_Unt_Wghtd_2024), reported unchanged. The most-prescribed drug in this group in 2024 was Jardiance (11.4 million claims). View the full dataset on CMS data.cms.gov.

Each drug in detail

Look up any Part D drug

Search the highest-volume Medicare Part D drugs by brand or generic name to see real average spending per dosage unit and 2024 claim volume.

Jardiance

Empagliflozin
Avg Medicare Part D spending
$18.94 / dosage unit
calendar year 2024
2024 Part D claims
11,368,280
how common it is

This is average Medicare Part D program spending per dosage unit, not a pharmacy cash price or a per-prescription cost. Information only — not medical advice and not a price quote.

Compare other drug classes

Frequently asked questions

Which sglt2 inhibitors are compared here?
This page compares 2 sglt2 inhibitors from the CMS Medicare Part D dataset (calendar year 2024): Jardiance, Farxiga. Each is shown with its real average Medicare Part D spending per dosage unit in US dollars.
What is the cheapest sglt2 inhibitor by Medicare spending per unit?
Among these drugs, Farxiga had the lowest average Medicare Part D spending per dosage unit at $18.31 (calendar year 2024), and Jardiance the highest at $18.94. This is program spending per billing unit, not a retail price, and dosage units differ between drugs.
Is this the price I would pay for sglt2 inhibitors?
No. These figures are average Medicare Part D program spending per dosage unit from CMS open data, not a pharmacy cash price or per-prescription cost. What you pay depends on your pharmacy, insurance, manufacturer, dose and region. This is information only, not medical advice.
Can a GeraClinic clinician help with type 2 diabetes, heart failure and chronic kidney disease?
A GeraClinic clinician can review your medication for type 2 diabetes, heart failure and chronic kidney disease, explain the options, and issue or renew a prescription online where clinically appropriate. GeraClinic only lists independently verified, licensed clinicians.

Need help with type 2 diabetes, heart failure and chronic kidney disease?

A GeraClinic clinician can review your medication, explain the options, and issue or renew a prescription online where clinically appropriate — without travelling to a clinic.

Contains public sector information published by U.S. Centers for Medicare & Medicaid Services (CMS) and licensed under the U.S. Government Works / Public Domain. Source: CMS Medicare Part D Spending by Drug (calendar year 2024, published 2026-06-25).

Informational/educational only — not a substitute for professional medical advice; a clinician interprets results.